InvestSMART

Actinogen Medical Limited (ASX: ACW) - Announcements

- Current share price for ACW : $0.046

ASX company news and announcements for Actinogen Medical Limited (ACW) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Actinogen Medical Limited (ACW) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Actinogen Medical Limited (ACW), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Actinogen Medical Limited (ACW)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$178 Application for quotation of securities - ACW 18 Jun 2026 3:02PM $0.036 $0.046 risen by 27.78%
$178 ACW third positive XanaMIA trial data committee review 18 Jun 2026 8:57AM $0.032 $0.046 risen by 43.75%
$178 ACW presents XanaMIA population and screening data at ADRF 1 Jun 2026 8:52AM $0.038 $0.046 risen by 21.05%
$178 Actinogen receives positive scientific advice from EMA 28 May 2026 9:51AM $0.038 $0.046 risen by 21.05%
$178 Application for quotation of securities - ACW 21 May 2026 2:54PM $0.036 $0.046 risen by 29.58%
$178 Letter to Shareholders, Notice of GM & Proxy Form 21 May 2026 2:44PM $0.036 $0.046 risen by 29.58%
$178 Application for quotation of securities - ACW 18 May 2026 2:29PM $0.036 $0.046 risen by 27.78%
$178 ACW CEO options exercise and expiry reminder 13 May 2026 10:16AM $0.044 $0.046 risen by 4.55%
$178 Appendix 3Y - Dr Steven Gourlay 13 May 2026 10:12AM $0.044 $0.046 risen by 4.55%
$178 Application for quotation of securities - ACW 13 May 2026 10:08AM $0.045 $0.046 risen by 2.22%
$178 Application for quotation of securities - ACW 11 May 2026 11:44AM $0.047 $0.046 fallen by 2.13%
$178 Notification of cessation of securities - ACW 4 May 2026 8:17AM $0.046 $0.046 fallen by 0%
$178 Correction-March2026 quarterly activity report & Appendix 4C 29 Apr 2026 9:17AM $0.045 $0.046 risen by 2.22%
$178 ACW December 2025 quarterly activity report & Appendix 4C 29 Apr 2026 9:05AM $0.045 $0.046 risen by 2.22%
$178 Notification of buy-back - ACW 2 Apr 2026 10:53AM $0.037 $0.046 risen by 24.32%
$178 ACW XanaMIA Alzheimers open label trial commences 1 Apr 2026 8:59AM $0.034 $0.046 risen by 35.29%
$178 Appendix 3Y x 5 26 Mar 2026 2:06PM $0.036 $0.046 risen by 27.78%
$178 Cleansing Notice 26 Mar 2026 1:55PM $0.036 $0.046 risen by 27.78%
$178 Application for quotation of securities - ACW 26 Mar 2026 1:50PM $0.036 $0.046 risen by 27.78%
$178 Results of General Meeting 18 Mar 2026 10:50AM $0.038 $0.046 risen by 21.05%
$178 CEO loan-funded long-term incentive shares amendment 16 Mar 2026 9:04AM $0.037 $0.046 risen by 24.32%
$178 Application for quotation of securities - ACW 5 Mar 2026 2:42PM $0.041 $0.046 risen by 12.20%
$178 Application for quotation of securities - ACW 2 Mar 2026 9:10AM $0.041 $0.046 risen by 12.20%
$178 ACW successfully completes $16.8m Placement and SPP 27 Feb 2026 9:33AM $0.042 $0.046 risen by 9.52%
$178 Application for quotation of securities - ACW 26 Feb 2026 1:47PM $0.042 $0.046 risen by 9.52%

51 - 75 of 914 results

Page 3 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.